The study of the relationship between genes and response to drugs has been the subject of intensive research over the past two decades. Robust evidence now exists to support testing under clinical conditions.
Pharmacogenomics testing is the most recent addition to the dnalife® portfolio. We analyse genotypes associated with drug responsiveness for cardiovascular disease, psychiatry and pain management, amongst others. Reports provide practitioners with detailed guidelines on gene-drug interactions; highlighting potential side effects, increased toxicity, and lack of efficacy.
mygeneRx analyses genetic variants linked to the metabolism of the following drug classes (indicated below their respective medication areas) as well as all of those included in the sub-products mycardioRx, mypsychRx and mypainRx.
mygeneRx: 62 genetic variations, over 150 drugs